Ketoconazole
- Generic Name
- Ketoconazole
- Brand Names
- Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28Cl2N4O4
- CAS Number
- 65277-42-1
- Unique Ingredient Identifier
- R9400W927I
- Background
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...
- Indication
Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.
- Associated Conditions
- Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
- Associated Therapies
- -
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT01707407
- Locations
- 🇺🇸
Covance Research Unit, Inc, Madison, Wisconsin, United States
Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2014-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT01679613
- Locations
- 🇩🇪
1199.161.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01657838
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01637636
- Locations
- 🇺🇸
QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole
- Conditions
- Interventions
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT01627587
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 21
- Registration Number
- NCT01626651
A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT01625806
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01591850
Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2015-01-21
- Target Recruit Count
- 6
- Registration Number
- NCT01584297
- Locations
- 🇪🇸
Hospital Morales Meseguer, Murcia, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01520896
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.